Background Bronchodilators are commonly used as maintenance and rescue therapy in
patients with COPD. We aimed to examine the prescribing patterns of bronchodilators in …

Background Chronic obstructive pulmonary disease (COPD) is the third-leading cause of
death in the United States. Guideline recommendations for medication therapy include the …

Background: Cardiovascular disease (CVD) is the most prevalent comorbidity for chronic
obstructive pulmonary disease (COPD). Potential adverse cardiovascular events of …

Background Treatment of stable chronic obstructive pulmonary disease (COPD) with long-
acting bronchodilator (LABD) medications is recommended by the 2014 Global initiative for …

Purpose The aim of this study was to evaluate the first initiation, sequence of addition, and
appropriate prescribing of COPD medications in Manitoba, Canada. Patients and methods A …

Abstract Background and objective Bronchodilators (BDs) are the cornerstone of COPD
treatment. However, their underuse has been reported in real-life studies. PUMA is a primary …

Background While inhaled bronchodilators reduce symptoms and acute exacerbations of
chronic obstructive pulmonary disease (COPD), their use is associated with increased …

Background: Treatment guidelines recommend concomitantuse of ipratropium bromide and
inhaled β 2-agonists asseverity of COPD progresses. While the use of these two agents in …

This review summarizes the long-term clinical outcomes associated with β-agonist and
anticholinergic bronchodilator use in patients with chronic obstructive pulmonary disease …

Long acting inhaled bronchodilators--beta agonists and anti-cholinergic--can improve
symptoms, enhance quality of life, increase exercise ability, and reduce exacerbation rates …